nafazatrom has been researched along with arachidonic acid in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (83.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bjøro, T; Englund, K; Haug, E; Larsen, V; Torjesen, PA | 1 |
| Coker, SJ; Parratt, JR | 1 |
| Judd, AM; Koike, K; Login, IS; MacLeod, RM; Yasumoto, T | 1 |
| Cannizzaro, S; Davì, G; Giubilato, A; Strano, A | 1 |
| Bednar, M; Mullane, KM; Pinto, A; Smith, B | 1 |
| Burka, JF | 1 |
| Bakhle, YS; Pankhania, JJ | 1 |
| Boulu, RG; Massad, L; Plotkine, M | 1 |
| Ensley, RD; Rubin, LJ | 1 |
| Cavanaugh, PG; Honn, KV; Menter, D; Moilanen, D; Neagos, G; Sloane, BF; Taylor, JD | 1 |
| Das, M; Eling, TE; Honn, KV; Marnett, LJ; Ochs, RC; Pagels, WR; Siedlik, PH; Tainer, BE; Warnock, RH | 1 |
| Bjøro, T; Englund, K; Haug, E; Torjesen, PA | 1 |
2 review(s) available for nafazatrom and arachidonic acid
| Article | Year |
|---|---|
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases | 1986 |
A review of prostaglandins and the treatment of tumor metastasis.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Blood Platelets; Cathepsin B; Cathepsins; Cell Line; Cell Membrane; Epoprostenol; Humans; Mice; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neoplastic Cells, Circulating; Platelet Aggregation; Prostaglandins; Pyrazoles; Pyrazolones; Rats; Serotonin; Thromboxane A2 | 1983 |
1 trial(s) available for nafazatrom and arachidonic acid
| Article | Year |
|---|---|
[Platelet function inhibitors in peripheral arteriopathies].
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Antagonists; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis Obliterans; Aspirin; Blood Platelets; Calcium Channel Blockers; Clinical Trials as Topic; Cyclic AMP; Dipyridamole; Extremities; Heparin; Humans; Imidazoles; Prostaglandins; Prostanoic Acids; Pyrazoles; Pyrazolones; Quinacrine; Thiophenes; Thromboembolism; Thrombosis; Ticlopidine; Vascular Diseases | 1986 |
10 other study(ies) available for nafazatrom and arachidonic acid
| Article | Year |
|---|---|
The lipoxygenase inhibitor nafazatrom inhibits stimulated prolactin secretion in cultured rat lactotrophs (GH4C1 cells).
Topics: Animals; Arachidonic Acid; Cyclic AMP; Lipoxygenase Inhibitors; Phospholipases A; Phospholipases A2; Pituitary Gland; Prolactin; Pyrazoles; Pyrazolones; Rats; Signal Transduction; Tumor Cells, Cultured | 1992 |
Arachidonic acid cascade and the generation of ischemia- and reperfusion-induced ventricular arrhythmias.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Arrhythmias, Cardiac; Coronary Disease; Dogs; Epoprostenol; Iloprost; Norepinephrine; Perfusion; Pyrazoles; Pyrazolones; Receptors, Prostaglandin; Receptors, Thromboxane; Thromboxanes | 1985 |
Maitotoxin, a calcium channel activator, increases prolactin release from rat pituitary tumor 7315a cells by a mechanism that may involve leukotriene production.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Calcium; Cell Line; Indomethacin; Ion Channels; Marine Toxins; Oxocins; Pituitary Neoplasms; Prolactin; Prostaglandins; Pyrazoles; Pyrazolones; Rats; SRS-A | 1986 |
Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Anti-Inflammatory Agents; Arachidonic Acid; Arachidonic Acids; Cell Aggregation; Coronary Disease; Dogs; Fibrinolytic Agents; Glucuronidase; Male; Myocardial Infarction; Myocardium; Neutrophils; Platelet Aggregation; Pyrazoles; Pyrazolones; Superoxides | 1985 |
Pharmacological modulation of responses of guinea-pig airways contracted with arachidonic acid.
Topics: Animals; Arachidonate Lipoxygenases; Arachidonic Acid; Arachidonic Acids; Catechols; Chromones; Epoprostenol; Guinea Pigs; Indomethacin; Lipoxygenase Inhibitors; Lung; Male; Masoprocol; Muscle Contraction; Propionates; Pyrazoles; Pyrazolones; Receptors, Leukotriene; Receptors, Prostaglandin; Trachea | 1985 |
Drug effects on output of prostacyclin from isolated lungs.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arachidonic Acid; Arachidonic Acids; Dipyridamole; Epoprostenol; Guinea Pigs; In Vitro Techniques; Lung; Male; Pyrazoles; Pyrazolones; Rats; Rats, Inbred Strains | 1987 |
Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Epoprostenol; Fibrinolytic Agents; Male; Molsidomine; Pyrazoles; Pyrazolones; Rats; Rats, Inbred Strains; Thrombosis | 1988 |
Nafazatrom (Bay g 6575) blunts canine hypoxic pulmonary vasoconstriction: evidence for a prostaglandin-mediated mechanism.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Dogs; Hypertension, Pulmonary; Hypoxia; Male; Prostaglandin-Endoperoxide Synthases; Pulmonary Circulation; Pyrazoles; Pyrazolones; Vascular Resistance | 1985 |
Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Epoprostenol; Fibrinolytic Agents; Hydrogen Peroxide; Kinetics; Leukotrienes; Lipid Peroxides; Male; Oxidation-Reduction; Prostaglandin Endoperoxides, Synthetic; Prostaglandin H2; Prostaglandin-Endoperoxide Synthases; Prostaglandins H; Pyrazoles; Pyrazolones; Seminal Vesicles; Sheep | 1984 |
Inhibitors of the arachidonic acid metabolism attenuate the thyroliberin (TRH) stimulated prolactin production without modifying the production of inositolphosphates in GH4C1 pituitary cells.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Arachidonic Acid; Inositol Phosphates; Lipoprotein Lipase; Lipoxygenase Inhibitors; Phospholipases A; Phospholipases A2; Pituitary Neoplasms; Prolactin; Pyrazoles; Pyrazolones; Quinacrine; Rats; Thyrotropin-Releasing Hormone; Tumor Cells, Cultured | 1993 |